Arrowhead Research Corporation is a nanotechnology holding company that monetizes disruptive technologies through its majority-owned subsidiaries. It operates more than five subsidiaries in the energy, health care and electronics sectors. The company s subsidiaries include Insert Therapeutics, Agonn Systems, Tego Biosciences Corporation, Unidym, Nanotope and Leonardo Biosystems. It specializes in the identification, development and commercialization of new technologies in the areas of life sciences and nanotechnology-related products and applications. The company additionally operates Calando Pharmaceuticals, which employs proprietary nanotechnology on therapeutic use of ribonucleic acid interference for the diagnosis of diseases. Arrowhead Research Corporation s subsidiaries have undertaken various research-based studies in the fields of stem cells, carbon electronics and molecular diagnostics. It works in partnerships with several academic institutions, including the California Institute of Technology, Stanford University and Duke University, as well as the University of Florida. The company provides management, operational support, business development and financing services to its subsidiaries.